-

Agilent to Present at Upcoming Investor Events; Provides Webcast Details for Annual Shareholder Meeting

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the following webcasts for the investment community.

10th Annual SVB Leerink Global Healthcare Conference
Wednesday, Feb. 24 at 7:40 a.m. Pacific time/10:40 a.m. Eastern time
Bob McMahon, Agilent chief financial officer

41st Annual Cowen And Company Healthcare Conference
Thursday, March 4 at 8:10 Pacific time/11:10 a.m. Eastern time
Mike McMullen, Agilent president and CEO

To access these presentations, a Link will be provided in the “News & Events -- Events” portion of the Investor Relations section of the Agilent website.

In addition, the company announced details for the webcast of Agilent’s Annual Shareholder Meeting March 17. To join the meeting, please see the information below.

Agilent Technologies 2021 Annual Meeting of Shareholders
Wednesday, March 17 at 8 a.m. Pacific time/11 a.m. Eastern time
Virtual Meeting log-in beginning at 7:30 a.m. Pacific time
Virtual Meeting access: www.meetingcenter.io/238392758
Password: A2021

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Investor Contact:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

Industry:

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB
Release Summary
Agilent announces upcoming investor events and details for annual Shareholder Meeting.
Release Versions
English
$Cashtags
$A
Hashtags
#Agilent
#AnnualShareholderMeeting
#InvestorEvents

Contacts

Investor Contact:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom